Βεργου Στ. Θεογνωσια

Βεργου Στ. Θεογνωσια

Δερματολόγος - Αφροδισιολόγος, MD, PhD

  • Γεννήθηκε στα Τρίκαλα το 1975. Είναι παντρεμένη με τον Οφθαλμίατρο Απόστολο Μανιατέα.
    Απόφοιτος της Ιατρικής σχολής του Πανεπιστημίου Κρήτης. Ειδικεύτηκε στη Δερματολογία – Αφροδισιολογία στο νοσοκομείο «Α. Συγγρός» με καθηγητή τον κο Ανδρέα Κατσάμπα και την καθηγήτρια κα Χριστίνα Αντωνίου. Στο τέλος της ειδικότητας, έλαβε υποτροφία από το ίδρυμα «Ι. Στρατηγός» και μετέβει στο Πανεπιστήμιο Harvard της Βοστώνης, ΗΠΑ. Εκεί είχε την ευκαιρία να συμμετάσχει σαν Research Fellow στο Διεθνές Πρόγραμμα (International Training Program) του Πανεπιστημίου Harvard στο νοσοκομείο Mass General Hospital (MGH) και σε άλλα νοσοκομεία της Βοστώνης και να πάρει μέρος στις δραστηριότητες όλων των εξειδικευμένων τμημάτων της Δερματολογίας καθώς και να συμμετάσχει σε πολυάριθμες ακαδημαϊκές δραστηριότητες.

    Έχει κάνει μετεκπαίδευση στα τμήματα Φυσιολογίας Δέρματος, Παιδοδερματολογίας και Ψωρίασης στην Πανεπιστημιακή Κλινική του νοσοκομείου Charite στο Βερολίνο, Γερμανία. Εκεί είχε την ευκαιρία να συμμετάσχει σε πολλαπλά ακαδημαϊκά δρόμενα και δραστηριότητες.

    Από το 2008 έως το 2018 ήταν Eπιστημονική Συνεργάτης και μετέπειτα Πανεπιστημιακή Υπότροφος στην Πανεπιστημιακή Κλινική του νοσοκομείου «Α. Συγγρός». Επί 10 έτη διετέλεσε στέλεχος του Ιατρείου Ψωρίασης, της Μονάδας Ημερήσιας Νοσηλείας και του τμήματος έρευνας και κλινικών μελετών για την ψωρίαση. Έχει λάβει μέρος σε πολλαπλές, διεθνείς ερευνητικές μελέτες για την θεραπεία της ψωρίασης και τους βιολογικούς παράγοντες, έχει σημαντικό αριθμό διεθνών και ελληνικών δημοσιεύσεων στον τομέα της ψωρίασης και έχει συμμετάσχει ως προσκεκλημένη ομιλήτρια σε πολλαπλά συνέδρια σχετικά με την ψωρίαση και τις νέες θεραπείες που σχετίζονται με αυτή.

    Είναι διδάκτορας του Πανεπιστημίου Αθηνών με θέμα διδακτορικής διατριβής την εμφάνιση ακμής στις ενήλικες γυναίκες. Είναι συγγραφέας πολλών ελληνικών και διεθνών δημοσιεύσεων καθώς και συγγραφέας κεφαλαίων σε διεθνή και ελληνικά δερματολογικά συγγράματα. Εχει ενεργό συμμετοχή σε πολλά δερματολογικά συνέδρια, ελληνικά και διεθνή και είναι μέλος στις παρακάτω επιστημονικές Εταιρείες:
    Ελληνική Δερματολογική και Αφροδισιολογική Εταιρεία, Ευρωπαϊκή Ακαδημία Δερματολογίας και Αφροδισιολογίας, Αμερικάνικη Ακαδημία Δερματολογίας και Αφροδισιολογίας και Ευρωπαϊκή Ακαδημία Ερευνητικής Δερματολογίας.

    Ομιλεί Αγγλικά και Γαλλικά.

  • Συμμετοχες σε συνεδρια, ημεριδες, συμποσια

    Προσκεκλημένη Ομιλήτρια
    • Oxidative stress in psoriasis etiopathogenesis. 6th International Conference on oxidative stree in skin biology and medicine. Andros, Greece, 28-31 August 2014.
    • Keratoacanthoma-Clear cell acanthoma. Dermato-Oncology Conference. Athens, Greece, 31 October-1 November 2014.
    • The role of IL-17 in psoriasis. Dermatology Days, A. Sygros Hospital, Volos, Greece, 12-14 September 2014.
    • The results of the use of biologic therapies in the treatment of psoriatic arthritis. Sponsored Pfizer Hellas Symposium, Volos, Greece, 5-6 July 2014.
    • Treatment options after the fail of the use of biologics in psoriasis. Sponsored MSD Hellas Symposium, Athens, Greece, 20 June 2014.
    • What is the role of biologics in the prevention of comorbidities in patients with psoriasis? 14th Dermatologic Conference, Athens, Greece, 9-10 May 2014.
    • Psoriasis and Psoriatic arthritis. A multidisciplinary meeting. Sponsored Abbvie Hellas, Athens, Greece, 23 November 2013.
    • Systemic therapies for acne: What’s new? 9th World Congress of Cosmetic Dermatology, Athens, Greece, 27-30 June 2013.
    • The non-compliant patients: Personalised treatment and patients outcomes. 9th World Congress of Cosmetic Dermatology, Athens, Greece, 27-30 June 2013.
    • Herpes zoster. Dermatology Days, A. Sygros Hospital, Tzia, Greece, 7-9 June 2013.
    • Adult acne. GSK meeting, Acne and the New guidelines, Limeni, Greece, 17-19 May 2013.
    • Algorithm of the management of psoriasis in patients under biologics. Pfizer meeting, Portaria, Pilion, Greece, 23-25 November 2012.
    • Long term management of psoriasis with biologics. Advanced Clinical Observation Program, Athens, Greece, October 2012.
    • Parapsoriasis. Autumn meeting EDAE, Pilos, Greece, 7-9 September 2012.
    • The role of stress and thyroid autoimmunity in adult women with acne. Greek-Cyprus Dermatology Congress, Pafos, Cyprus, 29 June – 1 July 2012.
    • What do the psoriatic patients really need? Greek-Cyprus Dermatology Congress, Pafos, Cyprus, 29 June – 1 July 2012.
    • From joint to skin. Rheumatology – Dermatology Congress, Lefkada, Greece, 21-24 June 2012.
    • Interesting cases in dermatology. Rheumatology – Dermatology Congress, Lefkada, Greece, 21-24 June 2012.
    • What’s new in biologics for psoriasis. Dermatology Days, A. Sygros Hospital, Tzia, Greece, 25-27 May 2012.
    • Indications of phototests. 12th Dermatologic Conference, Athens, Greece, 11-12 May 2012.
    • Psoriasis, obesity and metabolic syndrome. An overview. MSD Psoriasis expert board meeting, Athens, Greece, 11 May 2012.
    • Phototherapy in pediatric patients. 7th Annual Conference of Alexandria Society of Dermatology, Alexandria, Egypt, 1-2 March 2012.
    • Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. ESDR Academy for future leaders in Dermatology, Cascais, Portugal, 10 – 12 November 2011.
    • Acute adverse reactions to biologics in psoriasis. SY19, Emergencies in Dermatology, 20th EADV Congress, Lisbon, Portugal, 20 – 24 October 2011.
    • Analysis of the nutrition and stress situation of volunteers by Resonance Raman spectroscopy. 5th International Conference on oxidative stress in skin biology and medicine, Andros, Greece, September 2011.
    • Safety of biologic therapies in psoriasis. 10th Greek Congress of Dermatology-Venereology, Athens, Greece, June 2011.
    • Long term management of psoriasis with biologics. Advanced Clinical Observation Program, Athens, Greece, February 2011.
    • The role of P. acnes and resistant bacteria in acne pathogenesis. EDAE meeting, Karpenisi, Greece, 29 January 2011.
    • SS13: Facial hypertrichosis and trichomegaly developing in female patients treated with EGFR inhibitors. 19th EADV Congress, Women’s Dermatological Society meeting, Gothenburg, Sweden, 6-10 October 2010.
    • Addressing therapeutic challenges in psoriasis: Optimizing long-term management. Winter Academy Dermatology, St Moritz, Pontresina, Switzerland, 8-11 April 2010.
    • Acne: a disease of both adulthood and adolescence. 31st Congress of Medical Limasol Council, Limasol, Cyprus, 20-21 March 2010.
    • SS10.12: Acne in adult women: what is the role of stress and thyroid disease? 18th EADV Congress, Women’s Dermatological Society meeting, Berlin, Germany, 7-11 October 2009.
    • Workshop 10: Ethical review and registry of clinical trials. 6th EADV Spring Symposium Bucharest, Romania, 23–26 April 2009.
    • Hypertrichosis associated with the EGFR inhibitor Erlotinib. 6th EADV Spring Symposium Bucharest, Romania, 23–26 April 2009.
    • The use of biologics for psoriasis. 35th Panhellenic Medical Congress, Athens, Greece, 5-9 May 2009.
    • The experience of the use of Infliximab at A. Sygros Hospital. Schering – Plough meeting, Patra, Greece, October 2008.

    Δημοσιευσεις σε διεθνη δερματολογικα περιοδικα

    1. Vergou T, Moustou AE, Antoniou C. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre. J Eur Acad Dermatol Venereol. 2016 Apr 2. Ahead of print.
    2. Lademann J, Vergou T, Darvin ME, Patzelt A, Meinke MC, Voit C, Papakostas D, Zastrow L, Sterry W, Doucet O. Influence of Topical, Systemic and Combined Application of Antioxidants on the Barrier Properties of the Human Skin. Skin Pharmacol Physiol. 2016; 29(1):41-46.
    3. Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T, Katsambas A, Antoniou C. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment. An Bras Dermatol. 2014; 89(6):891-7.
    4. Kluschke F, Weigmann HJ, Schanzer S, Meinke M, Vergou T, Sterry W, Lademann J. Gain or loss? Sunscreen efficiency after cosmetic pretreatment of the skin. Skin Pharmacol Physiol 2014; 27(2):82-9.
    5. Mangelsdorf S, Vergou T, Sterry W, Lademann J, Patzelt A. Comparative study of hair follicle morphology in eight mammalian species and humans. Skin Res Technol. 2014; 20(2):147-54.
    6. Opel D, Economidi A, Chan D, Wasfi Y, Mistry S, Vergou T, Antoniou C, Sofen H. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. J Drugs Dermatol. 2012; 11(12):1498-501.
    7. Drakaki E, Vergou T, Dessinioti C, Stratigos AJ, Salavastru C, Antoniou C. Spectroscopic methods for the photodiagnosis of nonmelanoma skin cancer. J Biomed Opt. 2013; 18(6):061221.
    8. Ulmer M, Patzelt A, Vergou T, Richter H, Müller G, Kramer A, Sterry W, Czaika V, Lademann J. In vivo investigation of the efficiency of a nanoparticle-emulsion containing polihexanide on the human skin. Eur J Pharm Biopharm 2013; 84(2):325-9.
    9. Vergou T, Patzelt A, Schanzer S, Meinke MC, Weigmann HJ, Thiede G, Sterry W, Lademann J, Darvin ME. Methods for the Evaluation of the Protective Efficacy of Sunscreen Products. Skin Pharmacol Physiol. 2013; 26(1):30-35.
    10. Weigmann HJ, Schanzer S, Vergou T, Antoniou C, Sterry W, Lademann J. Quantification of the Inhomogeneous Distribution of Topically Applied Substances by Optical Spectroscopy: Definition of a Factor of Inhomogeneity. Skin Pharmacol Physiol. 2012; 25(3):118-123.
    11. Vergou T, Mantzou E, Tseke P, Moustou A, Katsambas A, Alevizaki M, Antoniou C. Association of thyroid autoimmunity with acne in adult women. J Eur Acad Dermatol Venereol. 2012; 26(4):413-6.
    12. Gebauer V, Weigmann HJ, Schanzer S, Meinke MC, Vergou T, Sterry W, Lademann J. Influence of skin aging effects on the skin surface profile and the correlated distribution of topically applied sunscreens. J Biophotonics 2012; 5(3):274-82.
    13. Patzelt A, Lademann J, Richter H, Darvin ME, Schanzer S, Thiede G, Sterry W, Vergou T, Hauser M. In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin Res Technol. 2012; 18(3):364-9.
    14. Vergou T, Schanzer S, Richter H, Pels R, Thiede G, Patzelt A, Meinke MC, Sterry W, Fluhr JW, Lademann J. Comparison between TEWL and laser scanning microscopy measurements for the in vivo characterization of the human epidermal barrier. J Biophotonics 2012; 5(2):152-8.
    15. Czaika V, Alborova A, Richter H, Sterry W, Vergou T, Antoniou C, Lademann J, Koch S. Comparison of Transepidermal Water Loss and Laser Scanning Microscopy Measurements to Assess Their Value in the Characterization of Cutaneous Barrier Defects. Skin Pharmacol Physiol. 2012;25(1):39-46.
    16. Vergou T, Moustou AE, Sfikakis PP, Antoniou C, Stratigos AJ. Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Rev Clin Pharmacol. 2011; 4(4):515-523.
    17. Vergou T, Patzelt A, Richter H, Schanzer S, Zastrow L, Golz K, Doucet O, Antoniou C, Sterry W, Lademann J. Transfer of ultraviolet photon energy into fluorescent light in the visible path represents a new and efficient protection mechanism of sunscreens. J Biomed Opt. 2011; 16(10):105001.
    18. Bamias G, Evangelou K, Vergou T, Tsimaratou K, Kaltsa G, Antoniou C, Kotsinas A, Kim S, Gorgoulis V, Stratigos AJ, Sfikakis PP. Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol 2011; 20(9):725-31.
    19. Lademann J, Patzelt A, Schanzer S, Richter H, Meinke MC, Sterry W, Zastrow L, Doucet O, Vergou T, Darvin ME. Uptake of Antioxidants by Natural Nutrition and Supplementation: Pros and Cons from the Dermatological Point of View. Skin Pharmacol Physiol. 2011; 24(5):269-273.
    20. Dessinioti C, Vergou T, Moustou E, Katsambas A, Antoniou C. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol. 2011; 21(4):599-600.
    21. Jacobi U, Schanzer S, Weigmann HJ, Patzelt A, Vergou T, Sterry W, Lademann J. Pathways of Lateral Spreading. Skin Pharmacol Physiol. 2011; 24(5):231-237.
    22. Tadros A, Vergou T, Stratigos A, Tzavara C, Hletsos M, Katsambas A, Antoniou C. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011; 25(11):1282-7.
    23. Antoniou C, Vergou T, Dessinioti C, Stratigos AJ, Avgerinou G, Stavropoulos P, Katsambas A. Etanercept: effectiveness and safety data of a retrospective study. J Eur Acad Dermatol Venereol. 2011; 25(9):1113-5.
    24. Vergou T, Moustou AE, Maniateas A, Stratigos AJ, Katsambas A, Antoniou C. Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis. Int J Dermatol. 2010; 49(10):1215-7.
    25. Vergou T, Stratigos A, Karapanagiotou E, Matekovits A, Dilana K, Tsimboukis S, Antoniou C, Chasapi V, Syrigos K. Facial hypertrichosis and trichomegaly developing in patients treated with the EGFR inhibitor Erlotinib. J Am Acad Dermatol. 2010 Aug; 63(2):e56-8.
    26. Antoniou C, Dessinioti C, Vergou T, Stratigos AJ, Avgerinou G, Kostaki M, Katsambas A. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. J Eur Acad Dermatol Venereol. 2010 Dec; 24(12):1413-20.
    27. Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas A. Infliximab for the treatment of psoriasis in Greece. Four years of clinical experience at a single center. Br J Dermatol. 2010 May; 162(5):1117-23.
    28. Antoniou C, Moustou AE, Vergou T, Stratigos A, Kalambokas A, Katsambas AD. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies. J Eur Acad Dermatol Venereol. 2010 Mar; 24(3):356-7.
    29. Moustou AE, Stratigos A, Vergou T, Gregoriou S, Georgala S, Danopoulou I. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. J Eur Acad Dermatol Venereol. 2009 Aug; 23(8):968-9.
    30. Gregoriou S, Kontochristopoulos G, Vergou T, Menegakis G, Rigopoulos D. Should we consider hypohidrotic ectodermal dysplasia as a possible risk factor for malignant melanoma? J Cutan Med Surg. 2007 Sep-Oct; 11(5):188-90.
    31. Rigopoulos D, Gregoriou S, Korfitis C, Gintzou C, Vergou T, Katsambas A. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol. 2007 Jul; 32(4):456-7.
    32. Lademann J, Darvin M, Weigmann H, Schanzer S, Zastrow L, Doucet O, Meffert H, Krutmann J, Kochott D, Vergou T, Meinke M. Sunscreens-UV or light protection. IFSCC Magazine 2014 (4).
    33. Ulmer M, Patzelt A, Vergou T, Lademann J, Richter H, Kramer A, Muller G, Sterry W, Lange-Asschenfeldt B. In vitro investigation of the follicular penetration of porcine ear skin using a nanoparticle-emulsion containing the antiseptic polihexanide. Laser Phys. Lett. 2012; 9(5):381-386.
    34. Lademann J, Meinke M, Schanzer S, Antoniou C, Zastrow L, Sterry W, Vergou T. What’s new in skin aging. SOFW 2012; 138:2-7.
    35. Darvin ME, Sterry W, Lademann J, Vergou T. The role of carotenoids in human skin. Molecules 2011; 16:10491-10506.
    36. A. Patzelt, J. Lademann, H. Richter, M. Darvin, S. Schanzer, G. Thiede, W. Sterry, T. Vergou, M. Hauser. Oils on skin: penetration and occlusion of mineral oil and vegetable oils. Acta Paediatrica, 2011; 100(Suppl 463):27.
    37. Vergou T, Lima XTV, Kimball AB. Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. Expert Rev Dermatol. 2008 Aug; 3(4):453-463.
    38. Vergou T, Moustou AE, Tseke P, Stratigos A, Katsambas A, Antoniou C. Infliximab in the management of psoriasis in patients previously treated with other biologic agents. Psoriasis Forum, National Psoriasis Foundation, Fall 2010; 16(3):8-12.
    39. Antoniou C, Vergou T, Larios G, Rigopoulos D, Stratigos A, Katsambas A. Treatment of psoriasis and its challenges in Greece. IPC Psoriasis Review, September 2010; 6(2):10-11.
    40. Tadros A, Vergou T, Stratigos A, Tzavara C, Hletsos M, Katsambas A, Antoniou C. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? Hellenic Dermato-Venereological Review 2010; 21(4):245-252.
    41. Vergou T, Antoniou C. Psoriasis and psoriatic arthritis: differences and similarities in epidemiologic, genetic and immunologic basis. Hellenic Dermato-Venereological Review 2011; 22(1):39-41.
    42. Kontochristopoulos G, Vergou T, Gregoriou S, Anthopoulos T, Rigopoulos D. Hypohidrotic Ectodermal Dysplasia. Hellenic Dermato-Venereological Review. Jan-Mar 2006, 17:1, p.53-57.
    43. Rigopoulos D, Gregoriou S, Vergou T, Christofidou E, Mpaltatzis S, Kouskoukis K. Pseudoxanthoma Elasticum. Hellenic Dermato-Venereological Review. Jul-Sept 2005, 16:3, 79-84.

    Αναρτημενες ανακοινωσεις (Poster)

    • T Vergou, AE Moustou, S Masouri, C Antoniou. Study of the thyroid function and the hypothalamus-pituitary adrenal axis in young women with acne. What is the role of sex hormones? 23rd EADV Congress, Amsterdam, Netherlands, 8-12 October 2014. Poster P008.
    • T Vergou, S Masouri, AE Moustou, C Antoniou. Acne in adults: a multifactorial disease. 11th EADV Spring Symposium, Belgrade, Serbia, 22-25 May 2014. Poster P197.
    • P Trontzas, T Vergou et al. Associations of metabolic cardiovascular risk factors in patients with psoriasis and/or psoriatic arthritis. 9th World Congress of Cosmetic Dermatology, Athens, Greece, 27-30 June 2013. Poster PP34.
    • T Vergou, S Masouri, AE Moustou, C Antoniou. What is the role of stress and thyroid autoimmunity in adult women with acne? 22nd EADV Congress, Istanbul, Turkey, 2-6 October 2013. Poster P006.
    • Moustou AE, Alexandrou P, Vergou T et al. Expression of lymphagiogenic growth factors in psoriasis. 22nd EADV Congress, Istanbul, Turkey, 2-6 October 2013. Poster P1573.
    • AE Moustou, P Alexandrou, I Giannopoulou, A Stratigos, T Vergou, S Masouri, A Katsambas, C Antoniou. Lymphangiogenesis in psoriasis. 2nd Congress of Investigative Dermatology, September 2011, Creta, Greece. Poster AA20.
    • T Vergou, C Antoniou, A Mantzou, C Dessinioti, A Katsambas, M Alevizaki. The role of thyroid function in adult women with acne. 37th Panhellenic Endocrinology Congress, April 2010, Athens, Greece. Poster AA30.
    • T Vergou, AE Moustou, P Tseke, AJ Stratigos, C Antoniou. Clinical experience from the use of Infliximab in patients with psoriasis that failed to respond to other biologics. Symposium Psoriasis and Arthritis, January 2010, Heraklion, Crete. Poster (AA26).
    • T Vergou, AE Moustou, P Tseke, AJ Stratigos, C Antoniou. Infliximab in the management of psoriasis of patients previously treated with other biologic agents. 2nd World Psoriasis and Psoriatic Arthritis Conference, 24-28 June 2009, Stockholm, Sweden. Poster (Abstract No 48).
    • M. Kazanis, A. Armstrong, T. Vergou, C. Duffeyz, AB. Kimball. Understanding Incentives for Research Subjects in Clinical Trials Using Survey Data. 66th Annual Meeting of the AAD, February 1-5, 2008, San Antonio, Texas. Poster.
    • T Vergou, E Agiasofitou, AE Moustou, S Gregoriou, K Xenos, G Kontochristopoulos. Treatment of regional hyperidrosia in a patient with pachyonychia congenita. Panhellenic congress of Dermatology-Venereology June 2007. Poster (AA56).
    • Antoniou C, Stratigos A, Rigopoulos D, Moustou AE, Vergou T, Katsambas A. Infliximab in the treatment of psoriasis and psoriatic arthritis : results of an ongoing study in Greece. 15th Congress of the EADV, October 2006 Rhodes-Greece. Poster (Abstract No 951377).

    Συμμετοχη σε συγγραφη βιβλιων

    • Lademann J, Weigmann HJ, Schanzer S, Meinke M, Sterry W, Patzelt A, Vergou T. MÖGLICHKEITEN, GRENZEN UND NEBENWIRKUNGEN VON SONNEN-SCHUTZMITTELN. Vitamin D Update 2012. Dustri-Verlag, 33-41.
    • Christina Antoniou, Theognosia Vergou. Treatment of benign epidermal skin lesions. Dermatocosmetologie Clinica, Editura Curtea Veche 2012, 529-533.
    • European Hanbook of Dermatological Treatments 2015. Κεφάλαια: Ανεμευλογιά, Λοιμώξεις από απλό Ερπη (υπό δημοσίευση)
    • Vergou T, Moustou AE, Antoniou C. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre. J Eur Acad Dermatol Venereol. 2017; 31(1):e40-e41.
    • Petridis A, Panagakis P, Moustou E, Vergou T et al. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece. J Eur Acad Dermatol Venereol. 2018; 32(5):768-775.
    • Lademann J, Vergou T, Darvin ME et al. Influence of Topical, Systemic and Combined Application of Antioxidants on the Barrier Properties of the Human Skin. Skin Pharmacol Physiol. 2016; 29(1):41-46.
    • Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T et al. Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment. An Bras Dermatol. 2014; 89(6):891-7.
    • Kluschke F, Weigmann HJ, Schanzer S, Meinke M, Vergou T et al. Gain or loss? Sunscreen efficiency after cosmetic pretreatment of the skin. Skin Pharmacol Physiol 2014; 27(2):82-9.
    • Mangelsdorf S, Vergou T, Sterry W et al. Comparative study of hair follicle morphology in eight mammalian species and humans. Skin Res Technol. 2014; 20(2):147-54.
    • Opel D, Economidi A, Chan D, Wasfi Y, Mistry S, Vergou T et al. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. J Drugs Dermatol. 2012; 11(12):1498-501.
    • Drakaki E, Vergou T, Dessinioti C et al. Spectroscopic methods for the photodiagnosis of nonmelanoma skin cancer. J Biomed Opt. 2013; 18(6):061221.
    • Ulmer M, Patzelt A, Vergou T et al. In vivo investigation of the efficiency of a nanoparticle-emulsion containing polihexanide on the human skin. Eur J Pharm Biopharm 2013; 84(2):325-9.
    • Vergou T, Patzelt A, Schanzer S et al. Methods for the Evaluation of the Protective Efficacy of Sunscreen Products. Skin Pharmacol Physiol. 2013; 26(1):30-35.
    • Weigmann HJ, Schanzer S, Vergou T et al. Quantification of the Inhomogeneous Distribution of Topically Applied Substances by Optical Spectroscopy: Definition of a Factor of Inhomogeneity. Skin Pharmacol Physiol. 2012; 25(3):118-123.
    • Vergou T, Mantzou E, Tseke P et al. Association of thyroid autoimmunity with acne in adult women. J Eur Acad Dermatol Venereol. 2012; 26(4):413-6.
    • Gebauer V, Weigmann HJ, Schanzer S, Meinke MC, Vergou T et al. Influence of skin aging effects on the skin surface profile and the correlated distribution of topically applied sunscreens. J Biophotonics 2012; 5(3):274-82.
    • Patzelt A, Lademann J, Richter H, Darvin ME, Schanzer S, Thiede G, Sterry W, Vergou T, Hauser M. In vivo investigations on the penetration of various oils and their influence on the skin barrier. Skin Res Technol. 2012; 18(3):364-9.
    • Vergou T, Schanzer S, Richter H et al. Comparison between TEWL and laser scanning microscopy measurements for the in vivo characterization of the human epidermal barrier. J Biophotonics 2012; 5(2):152-8.
    • Czaika V, Alborova A, Richter H, Sterry W, Vergou T et al. Comparison of Transepidermal Water Loss and Laser Scanning Microscopy Measurements to Assess Their Value in the Characterization of Cutaneous Barrier Defects. Skin Pharmacol Physiol. 2012;25(1):39-46.
    • Vergou T, Moustou AE, Sfikakis P et al. Pharmacodynamics of TNF-α inhibitors in psoriasis. Expert Rev Clin Pharmacol. 2011; 4(4):515-523.
    • Vergou T, Patzelt A, Richter H et al. Transfer of ultraviolet photon energy into fluorescent light in the visible path represents a new and efficient protection mechanism of sunscreens. J Biomed Opt. 2011; 16(10):105001.
    • Bamias G, Evangelou K, Vergou T et al. Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol 2011; 20(9):725-31.
    • Lademann J, Patzelt A, Schanzer S, Richter H, Meinke MC, Sterry W, Zastrow L, Doucet O, Vergou T, Darvin ME. Uptake of Antioxidants by Natural Nutrition and Supplementation: Pros and Cons from the Dermatological Point of View. Skin Pharmacol Physiol. 2011; 24(5):269-273.
    • Dessinioti C, Vergou T, Moustou E et al. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol. 2011; 21(4):599-600.
    • Jacobi U, Schanzer S, Weigmann HJ, Patzelt A, Vergou T et al. Pathways of Lateral Spreading. Skin Pharmacol Physiol. 2011; 24(5):231-237.
    • Tadros A, Vergou T, Stratigos A et al. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011; 25(11):1282-7.
    • Antoniou C, Vergou T, Dessinioti C et al. Etanercept: effectiveness and safety data of a retrospective study. J Eur Acad Dermatol Venereol. 2011; 25(9):1113-5.
    • Vergou T, Moustou AE, Maniateas A et al. Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis. Int J Dermatol. 2010; 49(10):1215-7.
    • Vergou T, Stratigos A, Karapanagiotou E et al. Facial hypertrichosis and trichomegaly developing in patients treated with the EGFR inhibitor Erlotinib. J Am Acad Dermatol. 2010 Aug; 63(2):e56-8.
    • Antoniou C, Dessinioti C, Vergou T et al. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. J Eur Acad Dermatol Venereol. 2010 Dec; 24(12):1413-20.
    • Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T et al. Infliximab for the treatment of psoriasis in Greece. Four years of clinical experience at a single center. Br J Dermatol. 2010 May; 162(5):1117-23.
    • Antoniou C, Moustou AE, Vergou T et al. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies. J Eur Acad Dermatol Venereol. 2010 Mar; 24(3):356-7.
    • Moustou AE, Stratigos A, Vergou T et al. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. J Eur Acad Dermatol Venereol. 2009 Aug; 23(8):968-9.
    • Gregoriou S, Kontochristopoulos G, Vergou T et al. Should we consider hypohidrotic ectodermal dysplasia as a possible risk factor for malignant melanoma? J Cutan Med Surg. 2007 Sep-Oct; 11(5):188-90.
    • Rigopoulos D, Gregoriou S, Korfitis C, Gintzou C, Vergou T, Katsambas A. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol. 2007 Jul; 32(4):456-7.
    • Lademann J, Darvin M, Weigmann H, Schanzer S, Zastrow L, Doucet O, Meffert H, Krutmann J, Kochott D, Vergou T, Meinke M. Sunscreens-UV or light protection. IFSCC Magazine 2014 (4).
    • Ulmer M, Patzelt A, Vergou T et al. In vitro investigation of the follicular penetration of porcine ear skin using a nanoparticle-emulsion containing the antiseptic polihexanide. Laser Phys. Lett. 2012; 9(5):381-386.
    • Lademann J, Meinke M, Schanzer S, Antoniou C, Zastrow L, Sterry W, Vergou T. What’s new in skin aging. SOFW 2012; 138:2-7.
    • Darvin ME, Sterry W, Lademann J, Vergou T. The role of carotenoids in human skin. Molecules 2011; 16:10491-10506.
    • A. Patzelt, J. Lademann, H. Richter, M. Darvin, S. Schanzer, G. Thiede, W. Sterry, T. Vergou, M. Hauser. Oils on skin: penetration and occlusion of mineral oil and vegetable oils. Acta Paediatrica, 2011; 100(Suppl 463):27.
    • Vergou T, Lima XTV, Kimball AB. Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. Expert Rev Dermatol. 2008 Aug; 3(4):453-463.
    • Vergou T, Moustou AE, Tseke P et al. Infliximab in the management of psoriasis in patients previously treated with other biologic agents. Psoriasis Forum, National Psoriasis Foundation, Fall 2010; 16(3):8-12.
    • Antoniou C, Vergou T, Larios G et al. Treatment of psoriasis and its challenges in Greece. IPC Psoriasis Review, September 2010; 6(2):10-11.
logo
© 2016 Δέρμα Σώμα

ΕΠΙΚΟΙΝΩΝΙΑ

Λεύκης 11, 16672, Βάρη
2109656777 - 2109656778
info@dermasoma.gr

ΩΡΑΡΙΟ ΛΕΙΤΟΥΡΓΙΑΣ

Δευτέρα - Παρασκευή: 9:00 - 21:00

Σάββατο: 9:00 - 15:00

SOCIAL